Oppenheimer lowered the firm’s price target on Sagimet Biosciences (SGMT) to $25 from $30 and keeps an Outperform rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SGMT:
- Sagimet Biosciences Reports Q1 2025 Financial Results
- Sagimet Biosciences Reports Q1 Financial Results and Updates
- Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)
- Sagimet Biosciences announces presentations at EASL Congress 2025
- Sagimet Biosciences: Promising Future with Phase 3 MASH Trials and Strong Financial Position